<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): January 15, 2009</B>


<P style="font-size: 24pt" align="center"><B>IMMTECH PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-14907</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>39-1523370</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>One North End Avenue<BR>
New
York, New York <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>10282</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(212) 791-2911</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 4.01 Changes in
Registrant&#8217;s Certifying Accountant.</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">(a)&nbsp;On
January&nbsp;15, 2009, Immtech Pharmaceuticals, Inc. (the
&#8220;Company&#8221;) has discontinued using Deloitte &amp; Touche LLP
(&#8220;Deloitte&#8221;) as its independent registered public accounting firm.
The decision to change accounting firms was approved by the Company&#8217;s
Board of Directors.

<P style="font-size: 10pt; text-indent: 7%" align="left">The audit report of
Deloitte on the Company&#8217;s financial statements for the fiscal years ended
March&nbsp;31, 2008 and March&nbsp;31, 2007 did not contain an adverse opinion
or a disclaimer of opinion, nor was it qualified or modified as to uncertainty,
audit scope or accounting principles, except as follows:

<P style="font-size: 10pt; text-indent: 7%" align="left">The audit report of
Deloitte on the consolidated financial statements of the Company as of and for
the fiscal year ended March&nbsp;31, 2008 contained an explanatory paragraph
which stated &#8220;The accompanying financial statements, for the year ended
March&nbsp;31, 2008, have been prepared assuming the Company will continue as a
going concern. The Company is a development stage enterprise engaged in
developing and commercializing drugs for infectious diseases. As discussed in
Note&nbsp;1 to the financial statements, the Company&#8217;s recurring losses
from operations and cash position raise substantial doubt about its ability to
continue as a going concern. Management&#8217;s plans concerning these matters
are also discussed in Note&nbsp;1 to the financial statements. The financial
statements do not include any adjustments that might result from the outcome of
this uncertainty;&#8221; and contained an explanatory paragraph which stated
&#8220;As described in Notes 1 and 8 to the consolidated financial statements,
effective April&nbsp;1, 2006, the Company changed its method for share-based
compensation to adopt Financial Accounting Standards Board
(FASB)&nbsp;Statement No.&nbsp;123 (revised 2004), <I>Share-Based
Payment</I>.&#8221;

<P style="font-size: 10pt; text-indent: 7%" align="left">During the
Company&#8217;s fiscal years ended March&nbsp;31, 2008 and March&nbsp;31, 2007
and through January&nbsp;15, 2009, there were no disagreements with Deloitte on
any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not
resolved to the satisfaction of Deloitte, would have caused Deloitte to make a
reference to the subject matter of the disagreements in connection with their
report, or reportable events as described in Item&nbsp;304(a)(1)(v) of
Regulation&nbsp;S-K.

<P style="font-size: 10pt; text-indent: 7%" align="left">(b)&nbsp;On
January&nbsp;15, 2009, the Board of Directors of the Company approved the
appointment of Virchow, Krause &amp; Company, LLP (&#8220;Virchow
Krause&#8221;) as the Company&#8217;s new independent registered public
accounting firm, effective immediately. The Company has not consulted with
Virchow Krause during its two most recent fiscal years ended March&nbsp;31,
2008 and March&nbsp;31, 2007, or during any subsequent period prior to its
appointment as the Company&#8217;s independent auditor with respect to any of
the matters or events listed in Items 304(a)(2)(i) and (ii)&nbsp;of
Regulation&nbsp;S-K .

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 Financial Statements and
Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="5%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="92%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left" colspan="3">The following exhibits are filed
herewith:</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px"><BR><B>No.</B>&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><BR><B>Exhibit</B></TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
 <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">16.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Letter of Deloitte &amp; Touche LLP, dated
January&nbsp;20, 2009.</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
 </TR>



 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated January&nbsp;20,
2009, announcing the change in the Company&#146;s independent
registered public accounting firm.</TD>
 </TR>

<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="50%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="45%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD nowrap align="left">Date: January 20, 2009</TD>
  <TD>&nbsp;</TD>
  <TD nowrap align="left"><B>IMMTECH PHARMACEUTICALS, INC.</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><BR>/s/ Eric L. Sorkin</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Eric L. Sorkin<BR> Chairman, Chief Executive
Officer and President</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><U><B>EXHIBIT INDEX</B></U>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="5%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="92%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">16.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Letter of Deloitte &amp; Touche LLP dated
January&nbsp;20, 2009.</TD>
 </TR>
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
 </TR>



 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated January&nbsp;20,
2009, announcing the change in the Company&#146;s independent
registered public accounting firm.</TD>
 </TR>

<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c79605e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 12922}]
{"company-data": {"conformed-name": "IMMTECH PHARMACEUTICALS, INC.", "cik": "0000882509", "assigned-sic": "2836", "irs-number": "391523370", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14907", "film-number": "09534764"}, "business-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061", "phone": "(847) 573-0033"}, "mail-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061"}, "former-company": {"former-conformed-name": "IMMTECH INTERNATIONAL INC", "date-changed": "19980824"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): January 15, 2009
IMMTECH PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
001-14907
39-1523370
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One North End Avenue
New
York, New York
10282
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(212) 791-2911
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.01 Changes in
Registrant's Certifying Accountant.
(a) On
January 15, 2009, Immtech Pharmaceuticals, Inc. (the
"Company") has discontinued using Deloitte & Touche LLP
("Deloitte") as its independent registered public accounting firm.
The decision to change accounting firms was approved by the Company's
Board of Directors.
The audit report of
Deloitte on the Company's financial statements for the fiscal years ended
March 31, 2008 and March 31, 2007 did not contain an adverse opinion
or a disclaimer of opinion, nor was it qualified or modified as to uncertainty,
audit scope or accounting principles, except as follows:
The audit report of
Deloitte on the consolidated financial statements of the Company as of and for
the fiscal year ended March 31, 2008 contained an explanatory paragraph
which stated "The accompanying financial statements, for the year ended
March 31, 2008, have been prepared assuming the Company will continue as a
going concern. The Company is a development stage enterprise engaged in
developing and commercializing drugs for infectious diseases. As discussed in
Note 1 to the financial statements, the Company's recurring losses
from operations and cash position raise substantial doubt about its ability to
continue as a going concern. Management's plans concerning these matters
are also discussed in Note 1 to the financial statements. The financial
statements do not include any adjustments that might result from the outcome of
this uncertainty;" and contained an explanatory paragraph which stated
"As described in Notes 1 and 8 to the consolidated financial statements,
effective April 1, 2006, the Company changed its method for share-based
compensation to adopt Financial Accounting Standards Board
(FASB) Statement No. 123 (revised 2004),
Share-Based
Payment
."
During the
Company's fiscal years ended March 31, 2008 and March 31, 2007
and through January 15, 2009, there were no disagreements with Deloitte on
any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not
resolved to the satisfaction of Deloitte, would have caused Deloitte to make a
reference to the subject matter of the disagreements in connection with their
report, or reportable events as described in Item 304(a)(1)(v) of
Regulation S-K.
(b) On
January 15, 2009, the Board of Directors of the Company approved the
appointment of Virchow, Krause & Company, LLP ("Virchow
Krause") as the Company's new independent registered public
accounting firm, effective immediately. The Company has not consulted with
Virchow Krause during its two most recent fiscal years ended March 31,
2008 and March 31, 2007, or during any subsequent period prior to its
appointment as the Company's independent auditor with respect to any of
the matters or events listed in Items 304(a)(2)(i) and (ii) of
Regulation S-K .
ITEM 9.01 Financial Statements and
Exhibits.
(d) Exhibits
The following exhibits are filed
herewith:
No.
Exhibit
16.1
Letter of Deloitte & Touche LLP, dated
January 20, 2009.
99.1
Press release, dated January 20,
2009, announcing the change in the Company's independent
registered public accounting firm.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: January 20, 2009
IMMTECH PHARMACEUTICALS, INC.
/s/ Eric L. Sorkin
Eric L. Sorkin
Chairman, Chief Executive
Officer and President
EXHIBIT INDEX
No.
Exhibit
16.1
Letter of Deloitte & Touche LLP dated
January 20, 2009.
99.1
Press release, dated January 20,
2009, announcing the change in the Company's independent
registered public accounting firm.